Last updated: January 19, 2024
Sponsor: First Affiliated Hospital of Chengdu Medical College
Overall Status: Active - Recruiting
Phase
N/A
Condition
Neoplasm Metastasis
Diabetes And Hypertension
Williams Syndrome
Treatment
Selective adrenal artery embolization
Clinical Study ID
NCT06228677
CCC-SAAE
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age ≥18 years with no gender restrictions.
- Adherence to the "Primary Aldosteronism" Diagnosis and Treatment Guidelines, confirmeddiagnosis of primary aldosteronism following rigorous drug washout, and identificationas either aldosteronoma or idiopathic aldosteronism via adrenal vein blood sampling.
- Blood pressure metrics that satisfy any of the subsequent conditions: a)Clinic-recorded blood pressure ≥140/90mmHg; b) 24-hour ambulatory blood pressuremonitoring results displaying average blood pressure >130/80 mmHg or daytime readings >135/85 mmHg.
- Adrenal CT scan revealing adrenal hyperplasia, nodular formations, or no significantmorphological deviations.
- Hypertension history surpassing a duration of 6 months.
- Prior to screening, patients or their lawful guardians must provide a signed informedconsent, sanctioned by the ethics committee.
Exclusion
Exclusion Criteria:
- Patients diagnosed with primary hypertension or secondary hypertension attributed toother etiologies.
- Female participants who are presently pregnant, lactating, or with intentions toconceive within the forthcoming year.
- Presence of significant systemic diseases, with particular attention to hepatic andrenal dysfunction.
- Pronounced allergic reaction to contrast agents.
- Any other serious systemic diseases with a life expectancy of less than 12 months.
- Participants concurrently enrolled or expressing interest to participate in otherclinical trials, the outcomes of which could potentially influence the results of thecurrent study.
- The researcher's discretion deems the subject inappropriate for inclusion in the studyfor any given reason.
Study Design
Total Participants: 196
Treatment Group(s): 1
Primary Treatment: Selective adrenal artery embolization
Phase:
Study Start date:
September 18, 2023
Estimated Completion Date:
December 31, 2026
Study Description
Connect with a study center
The First Affiliated Hospital of Chengdu Medical College
Chengdu, Sichuan 610500
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.